Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids

 Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids

Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids

Shots:

  • Cellesce & Hubrecht Organoid Technology (HUB) enters into an agreement for the expansion of breast organoids utilizing bioprocessing technology and HUB’s Organoid Technology at large scale
  • The focus of the agreement is to develop genetically and phenotypically stable breast cancer organoids which retains the characteristics of tumors for drug discovery programmes
  • HUB’s Organoid Technology is a drug-screening technology based on LGR5+ intestinal stem cells forming polarized epithelium for pre-clinical drug discovery and validation enabling generation of in-vitro models

Click  here to read full press release/ article | Ref: Cellesce | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post